Cancers, Vol. 12, Pages 1897: Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI –IM–MS/MS Assay

Cancers, Vol. 12, Pages 1897: Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay Cancers doi: 10.3390/cancers12071897 Authors: Margaux Fresnais André Roth Kathrin I. Foerster Dirk Jäger Stefan M. Pfister Walter E. Haefeli Jürgen Burhenne Rémi Longuespée The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. Osimertinib is now also proposed as a first-line therapy, thus extending the scope of applications in lung oncology. Personalized medicine approaches are still necessary to monitor if patients are exposed to adequate concentrations of osimertinib during their treatment. It would also help to understand the appearance of new resistances in patients after several months of dosing with osimertinib. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is currently the gold standard for the quantification of drugs in plasma enabling pharmacokinetic analyses and patient monitoring. In the present study, we propose an alternative to LC–MS/MS methods for the rapid and sensitive quantification of osimertinib in plasma using matrix-assisted laser desorption/ionization (MALDI) –MS. The presented assay requires only 3 min per sam...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research